DENVER, Colo. — HempFusion announced the sponsorship and participation in ValidCare’s scientific study that addresses the Food and Drug Administration’s previous questions about CBD products. ValidCare will be conducting a human trial and study to determine if daily use of full-spectrum hemp-derived CBD or CBD isolate has any impact on the human liver. HempFusion is one of ten select CBD companies sponsoring and participating in ValidCare’s ground breaking study.
“We are excited that HempFusion is one of the select companies participating in this study as they have demonstrated leadership in regulatory compliance and concern for consumer safety,” stated Patrick McCarthy, CEO of ValidCare. “What makes this study unique is we are capturing real world evidence from real consumers, specifically on how they use CBD products and how their bodies react to those products, particularly with respect to liver safety. We believe this real world evidence is important to the FDA and could be used to guide policy moving forward,” continued McCarthy.
ValidCare expects the study to begin in the third quarter of 2020 and targets completion by the end of the year. The third-party scientific data generated from the companies participating in this study is intended to address some of the FDA’s specific requests about CBD products.
“We are incredibly proud to participate in ValidCare’s study and help advance scientific research surrounding CBD”, stated Jason Mitchell, co-CEO of HempFusion. “As a Company, we are built on a foundation of regulatory compliance as well as consumer safety and participation in this study helps establish HempFusion as a leader in the global CBD industry”, continued Mitchell.